Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05327686

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial (SAMURAI)

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Sponsor: NRG Oncology

Conditions Metastatic Renal Cell Carcinoma Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Unresectable Renal Cell Carcinoma

Interventions Avelumab Axitinib Biospecimen Collection Bone Scan Cabozantinib Computed Tomography Ipilimumab Lenvatinib Magnetic Resonance Imaging Nivolumab Pembrolizumab Stereotactic Ablative Radiotherapy

Updated 15 times since 2022 Last updated: Jan 13, 2026 Started: Feb 1, 2023 Primary completion: Jun 15, 2028 Completion: Jun 15, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Renal Cell Carcinoma and Stage III Renal Cell Cancer AJCC v8, this trial is actively recruiting participants. The trial is conducted by NRG Oncology and has accumulated 15 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

15 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Aug 2025 [monthly]

Recruiting PHASE2

▶ Show 10 earlier versions

Feb 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Apr 2024 [monthly]

Recruiting PHASE2
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Apr 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Apr 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: NRG Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alexandria, United States , Allentown, United States , Alton, United States , Ames, United States , Ankeny, United States , Ann Arbor, United States , Antigo, United States , Arroyo Grande, United States , Ashland, United States and 228 more locations